#USA #Research Triangle Park #Dignify Therapeutics #DTI-117 #Neurogenic Bowel Dysfunction

Dignify Therapeutics Moves to Clinical Trials with FDA Approval for DTI-117

Dignify Therapeutics, a pioneering biopharmaceutical company, has made significant progress by receiving clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for DTI-117. This groundbreaking drug aims to address neurogenic bowel dysfunction (NBD), a condition that severely affects the bowel control of individuals with neurological disorders.

Background and Purpose of DTI-117

Neurogenic bowel dysfunction is a condition often associated with spinal cord injuries, neurological diseases, and various other medical conditions that hinder voluntary bowel evacuation. For many living with NBD, traditional methods of managing bowel movements can be invasive and often unpredictable, relying heavily on laxatives, enemas, or even manual evacuated methods. These existing solutions can feel stigmatizing and inconvenient, prompting the need for innovation in medical treatments that restore autonomy.

DTI-117 is particularly notable due to its design as a rapid, on-demand treatment, allowing users to control their bowel evacuation needs. This novel approach targets the neurokinin-2 receptor and is expected to induce a bowel movement swiftly, within a matter of minutes. In previous animal model studies, DTI-117 demonstrated remarkable efficacy in facilitating quick and controlled bowel emptying, highlighting its potential to significantly improve the quality of life for those with NBD.

Transition to Clinical Development

With the successful FDA IND approval, Dignify Therapeutics is set to transition into the clinical phase of development. A Phase 1 clinical trial, which is randomized, double-blind, placebo-controlled and single-ascending-dose, is scheduled to commence on healthy volunteers starting November 2026. Funded by the National Institutes of Health (NIH), this study is fundamental to assessing the drug's safety, tolerability, and pharmacokinetics.

Anthony DiTonno, CEO of Dignify Therapeutics, expressed enthusiasm regarding the IND clearance, stating that this marks a vital milestone for the company and its mission. As the company gears up for dosages in the upcoming trial, preliminary topline safety and efficacy data is expected by early 2027, marking an exciting new chapter in clinical advancements for DTI-117.

Patient-Centric Focus in Development

One of the core philosophies guiding Dignify’s development of DTI-117 has been its emphasis on patient needs. Dr. Karl Thor, Chief Scientific Officer, shared insights on how personal experiences, especially through engagements with individuals affected by spinal cord injuries—including his son—shaped the drug's development. The design features prioritized by Dignify Therapeutics include predictable timing for bowel evacuation, brief duration of action, and overall tolerability. This patient-centered approach aims to provide a solution that aligns with the lifestyles and personal preferences of affected individuals.

Looking Ahead: The Future of Dignify Therapeutics

As Dignify moves forward, the support it has received from various sectors—including prominent venture capital firms, the North Carolina Biotechnology Center, and multiple NIH funding grants totaling over $20 million—underscores the strong belief in DTI-117's potential. The company also boasts 18 NIH awards, reflecting the commitment to innovation in addressing bladder and bowel voiding dysfunction prevalent among patients with neurogenic conditions.

The excitement surrounding DTI-117 could usher in a new era for patients seeking more effective, dignified ways of managing their bowel health, enhancing their independence and quality of life significantly. As November approaches, the outlook for both Dignify Therapeutics and its patients remains optimistic, with the promise of breakthrough advancements on the horizon.